Oncology Institute Inc (TOI) FinancialsTOIOncology Institute Inc

Oncology Institute Inc (TOI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Dispensary revenue, accounting for 52.2% of total sales, equivalent to $62.57M. Other significant revenue streams include FFS revenue and Capitated revenue. Understanding this composition is critical for investors evaluating how TOI navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Oncology Institute Inc maintains a gross margin of 14.72%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.42%, while the net margin is -1.69%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TOI converts its operational activities into shareholder value.

In the context of the broader market, TOI competes directly with industry leaders such as FLGT and DNA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TOI's gross margin of 14.72% stands against FLGT's 27.02% and DNA's 91.47%. Such benchmarking helps identify whether Oncology Institute Inc is trading at a premium or discount relative to its financial performance.

No financial data available for the latest quarter.